Home
Drugs
Ruxolitinib
Clinical Trials

Clinical Trials Related to Ruxolitinib

Related studies linked through entity extraction aliases.

Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Status: COMPLETED
Phase: PHASE1

Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults

Status: COMPLETED
Phase: PHASE2

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

Status: TERMINATED
Phase: PHASE1

A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

Status: COMPLETED
Phase: PHASE2

CINC424A2X01B Rollover Protocol

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE4

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis

Status: COMPLETED
Phase: PHASE1

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Status: COMPLETED
Phase: PHASE3

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Status: COMPLETED
Phase: PHASE2

Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients

Status: COMPLETED
Phase: PHASE1

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Status: COMPLETED
Phase: PHASE2

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

Status: COMPLETED
Phase: PHASE2

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Status: COMPLETED
Phase: PHASE1/PHASE2

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Status: COMPLETED
Phase: PHASE1/PHASE2

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Status: TERMINATED
Phase: PHASE1/PHASE2

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Status: TERMINATED
Phase: PHASE2

Study of Ruxolitinib in Colorectal Cancer Patients

Status: TERMINATED
Phase: PHASE2

A Study of Ruxolitinib in Pancreatic Cancer Patients

Status: TERMINATED
Phase: PHASE3

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Status: TERMINATED
Phase: PHASE2

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Status: TERMINATED
Phase: PHASE3